Jay T. Klievink

Helsinki, Finland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Multimodal immunopharmacologic screens identify drugs rewiring the cancer-immune interface.

Multimodal immunopharmacologic screens identify drugs rewiring the cancer-immune interface.

Journal: bioRxiv : the preprint server for biology

Published: April 27, 2026

TIM3 blockade with hypomethylating therapy restores NK-cell and cytotoxic CD4+ T-cell activity in patients with AML or MDS.

TIM3 blockade with hypomethylating therapy restores NK-cell and cytotoxic CD4+ T-cell activity in patients with AML or MDS.

Journal: Cancer immunology research

Published: February 04, 2026

Functionally Characterizing the Renal Cell Carcinoma Tumor-Immune Microenvironment via Patient-Derived Ex Vivo Models.

Functionally Characterizing the Renal Cell Carcinoma Tumor-Immune Microenvironment via Patient-Derived Ex Vivo Models.

Journal: Cancer research communications

Published: August 01, 2025

Predicting antigen-specific T-cell immunity against Wilms tumor 1 in hematologic cancer.

Predicting antigen-specific T-cell immunity against Wilms tumor 1 in hematologic cancer.

Journal: Leukemia

Published: March 14, 2025

Single-cell analysis of aplastic anemia reveals a convergence of NK and NK-like CD8+ T cells with a disease-associated TCR signature.

Single-cell analysis of aplastic anemia reveals a convergence of NK and NK-like CD8+ T cells with a disease-associated TCR signature.

Journal: Science translational medicine

Published: February 26, 2025

Ex vivo modeling of precision immuno-oncology responses in lung cancer.

Ex vivo modeling of precision immuno-oncology responses in lung cancer.

Journal: Science advances

Published: October 30, 2024

High-throughput drug screening identifies SMAC mimetics as enhancers of NK-cell cytotoxicity in chronic myeloid leukemia.

High-throughput drug screening identifies SMAC mimetics as enhancers of NK-cell cytotoxicity in chronic myeloid leukemia.

Journal: Blood

Published: May 17, 2024

Integrated drug profiling and CRISPR screening identify BCR::ABL1-independent vulnerabilities in chronic myeloid leukemia.

Integrated drug profiling and CRISPR screening identify BCR::ABL1-independent vulnerabilities in chronic myeloid leukemia.

Journal: Cell reports. Medicine

Published: September 20, 2023

Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation.

Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation.

Journal: Leukemia

Published: March 31, 2023

Single-cell functional genomics reveals determinants of sensitivity and resistance to natural killer cells in blood cancers.

Single-cell functional genomics reveals determinants of sensitivity and resistance to natural killer cells in blood cancers.

Journal: Immunity

Published: October 31, 2022

Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation.

Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation.

Journal: Blood cancer journal

Published: December 21, 2021

IFN-α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia.

IFN-α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia.

Journal: The Journal of clinical investigation

Published: July 06, 2021

Showing 1-12 of 17

Last Updated: 09/26/2026